The FDA grants Fast Track designation to BNT113 for treating HPV16+ head and neck squamous cell carcinoma expressing PD-L1 in the first-line setting.
The FDA has granted breakthrough therapy designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of patients ...
Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.
According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion ...
Narcan Nasal Spray is an opioid antagonist that reverses the effects of opioids, including respiratory depression, sedation, and hypotension.
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results